The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trialJohn G.F. Cleland, Theis Lange, Joe Cuthbert et al.|European Heart Journal|2020Cited by 143
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart FailureJoão Pedro Ferreira, Faı̈ez Zannad, Job A.J. Verdonschot et al.|Circulation Heart Failure|2019Cited by 97